



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,702 - Conf. # 9370
				Filing Date	October 27, 2005
				First Named Inventor	Olivier Bezencon
				Art Unit	1624
				Examiner Name	K. Habte
Sheet	1	of	1	Attorney Docket Number	A0345.0015

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-97/09311	03-13-1997	Hoffmann La Roche		X
	BB	WO-03/093267	11-13-2003	Actelion Pharmaceuticals Ltd et al.		X
	BC	WO-04/002957	01-08-2004	Actelion Pharmaceuticals Ltd		X

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Waeber B., et al., "THE RENIN-ANGIOTENSIN SYSTEM IN EXPERIMENTAL AND HUMAN HYPERTENSION", in Berkenhager W.H. Reid J.L. (eds): Handbook of Hypertension, Amsterdam, Elsevier Science Publishing Co., (1996), pp. 489-519		
	CB	Weber, M.A., Am. J. Hypertens., (1992), 5, 247S		
	CC	Rosenberg, M.E., et al., Kidney International, (1994), 45, 403		
	CD	Breyer, J.A., et al., Kidney International, (1994), 45, S156		
	CE	Vaughan, D.E., et al., Cardiovasc. Res., (1994), 28, 159		
	CF	Fouad-Tarazi, F., et al., Am. J. Med., (1988), 84 (Suppl. 3A), 83		
	CG	Pfeffer, M.A., et al., N. Engl. J. Med., (1992), 327, 669		
	CH	Kleinert, H.D., Cardiovasc. Drugs, (1995), 9, 645		
	CI	Husain, A., J. Hypertens., (1993), 11, 1155		
	CJ	Israili Z.H., et al., Annals of Internal Medicine, (1992), 117, 234		
	CK	Azizi M., et al., J. Hypertens., (1994) 12, 419		
	CL	Neutel, J.M., et al., Am. Heart, (1991), 122, 1094		
	CM	Rahuel, Jr., et al., Chem. Biol., (2000), 7, 493		
	CN	Mealy, N.E., Drugs of the Future, (2001) 26, 1139		
	CO	Oefner, C., et al., Chem. Biol., (1999), 6, 127		
	CP	Marki, H.P., et al., Il Farmaco, (2001), 56, 21		
	CQ	Majewski, M., et al., J. Org. Chem., (1995) 60, 5825		
	CR	Kiesewetter, D.O., Tetrahedron Asymmetry, (1993) 4, 2183		
	CS	Chen, Zhengming., Synthesis and Dopamine Transporter, J. Med. Chem., (1996), 39, 4744-4749		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--